Compare Novo Nordisk A/S (NVO) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SiTime Corporation — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while SiTime Corporation trades at $698.63 (market cap $20.05B). The key difference: Novo Nordisk A/S is far larger — about 10.4× SiTime Corporation's market cap, and Novo Nordisk A/S pays a 3.81% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| NVO | SITM | |
|---|---|---|
Market Cap | $207.85B | $20.05B |
Sector | Health | Technology |
52-Week High | $63.98 | $901.60 |
52-Week Low | $35.29 | $212.77 |
Enterprise Value | $222.55B | $19.45B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
SITM trades at $700.42, up 1.52% today, with a bullish technical outlook and strong analyst consensus. Recent Q2 2026 earnings beat estimates with EPS of $2.34 versus $1.95 expected, driven by 127% revenue growth from AI infrastructure demand. The stock shows robust institutional interest and positive media coverage highlighting AI timing growth.
Outlook is positive with a consensus price target of $870, but risks include high valuation multiples (P/E 1,111.15, P/S 38.1) and integration challenges from the Renesas acquisition. Earnings momentum and AI exposure support upside, yet execution and premium pricing warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
